Clinical trials: Recurrent Endometrial Carcinoma
Cancer
Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma
RATIONALE: Intravenous VEGF Trap may stop the growth of solid tumors or non-Hodgkin's lymphoma by stopping blood flow to the cancer.
- Trial name
- NCT00082823
- Testing
- ziv-aflibercept
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- Regeneron Pharmaceuticals
Endometrial Cancer
Evaluation of Mirvetuximab Soravtansine (IMGN853) in Women With Folate Receptor-α Positive Endometrial Cancer
The purpose of this study is to evaluate the activity and safety profile of mirvetuximab soravtansine (IMGN853) in patients with type II endometrial cancers that overexpress folate receptor alpha (FRα).
- Trial name
- NCT03832361
- Testing
- IMGN853
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Alessandro Santin
High-risk Endometrial Cancer
Predictors of Recurrence for High Risk Endometrial Cancer Patients
This study will analyze whether there is any difference in recurrence and survival rates among the patients who received different adjuvant therapies.
- Trial name
- NCT04412902
- Testing
- adjuvant therapy
- Where
- Taiwan
- Volunteers
- 92 people
- Sponsor
- Far Eastern Memorial Hospital
Endometrial Cancer
A Phase II, Single-Arm Study of RAD001 (Everolimus), Letrozole, and Metformin in Patients With Advanced or Recurrent Endometrial Carcinoma
The goal of this clinical research study is to learn if the combination of everolimus, letrozole, and metformin can help to control recurrent or progressive endometrial cancer.
- Trial name
- NCT01797523
- Testing
- Metformin, Letrozole, Everolimus
- Where
- 6 sites in United States
- Volunteers
- 62 people
- Sponsor
- M.D. Anderson Cancer Center
Endometrial Cancer
Paclitaxel in Treating Patients With Refractory or Recurrent Endometrial Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of paclitaxel in treating patients who have refractory or…
- Trial name
- NCT00022620
- Testing
- paclitaxel
- Where
- 8 sites in Austria, Belgium and 4 more
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Endometrial Cancer
Study of Niraparib and TSR-042 in Recurrent Endometrial Cancer
This is a phase 2 study of investigational drug niraparib and TSR-042 in patients with advanced/recurrent endometrial cancer. The purpose of this study is to determine whether blocking a protein called poly (ADP-ribose)…
- Trial name
- NCT03016338
- Testing
- Niraparib, TSR-042
- Where
- 7 sites in Canada
- Volunteers
- 51 people
- Sponsor
- University Health Network, Toronto
Corpus Uteri, Endometrial Cancer
Pharmacology Study of Aerosolized Liposomal 9-Nitro-20 (S)-Camptothecin (L9NC)
The purpose of this study is to determine the amount of Aerosolized Liposomal-Nitro-20 (S)-Camptothecin (L9NC) in a patients blood and tumor.
- Trial name
- NCT00250016
- Where
- United States
- Sponsor
- University of New Mexico
Ovarian Cancer, Endometrial Cancer
Single Arm Trial With Combination of Everolimus and Letrozole in Treatment of Platinum Resistant Relapse or Refractory or Persistent Ovarian Cancer/Endometrial Cancer
The purpose of the study is to determine if the combination of Everolimus and Letrozole is effective in the treatment of women with either recurrent or persistent epithelial ovarian, fallopian tube, primary peritoneal or…
- Trial name
- NCT02188550
- Testing
- everolimus and letrozole
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Sinai Hospital of Baltimore
Recurrent Endometrial Carcinoma
Bevacizumab in Treating Patients With Recurrent or Persistent Endometrial Cancer
This phase II trial is studying how well bevacizumab works in treating patients with recurrent or persistent endometrial cancer. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways.
- Trial name
- NCT00301964
- Testing
- bevacizumab, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- National Cancer Institute (NCI)
Malignant Peritoneal Neoplasm, Malignant Retroperitoneal Neoplasm
Nivolumab With or Without Ipilimumab in Treating Patients With Recurrent or High Grade Gynecologic Cancer With Metastatic Peritoneal Carcinomatosis
This phase Ib trial studies the side effects and best dose of nivolumab with or without ipilimumab in treating patients with female reproductive cancer that has come back (recurrent) or is high grade and has spread extensively…
- Conditions
- Malignant Peritoneal Neoplasm, Malignant Retroperitoneal Neoplasm, Metastatic Cervical Carcinoma, Metastatic Endometrial Carcinoma
- Trial name
- NCT03508570
- Testing
- Ipilimumab, Laboratory Biomarker Analysis, Nivolumab
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- M.D. Anderson Cancer Center
Endometrial Cancer
Gemcitabine and Cisplatin for Advanced or Recurrent Endometrial Cancer
Primary Objective: To estimate the antitumor activity of the combination of gemcitabine and cisplatin in patients with advanced (stage III or IV) or recurrent endometrial cancer.
- Trial name
- NCT00388154
- Testing
- Gemcitabine, Cisplatin
- Where
- 3 sites in United States
- Volunteers
- 21 people
- Sponsor
- M.D. Anderson Cancer Center
Head & Neck Squamous Cell Carcinoma, Non-Small Cell Lung Cancer
Phase 1 Study of STRO-006 in Adults With Refractory Solid Tumors That Are Recurrent or Metastatic
This study is a first-in-human (FIH) Phase 1 open-label, multicenter study including three parts: Part 1A is a dose escalation of STRO-006 monotherapy in selected tumor types reported to commonly express ITGB6.
- Conditions
- Head & Neck Squamous Cell Carcinoma, Non-Small Cell Lung Cancer, Esophageal Cancer, Gastric Cancer
- Trial name
- NCT07807345
- Testing
- STRO-006, Pembrolizumab
- Where
- 6 sites in United States
- Volunteers
- 285 people
- Sponsor
- Sutro Biopharma, Inc.
Endometrial Cancer, ARID1A Gene Mutation
Avelumab and M1774 in ARID1A-mutated Endometrial Cancer
The purpose of this research study is to see if the combination of study drugs avelumab and M1774 is effective and safe for participants with endometrial cancer.
- Conditions
- Endometrial Cancer, ARID1A Gene Mutation, Recurrent Endometrial Carcinoma
- Trial name
- NCT06518564
- Testing
- Avelumab, M1774
- Where
- 2 sites in United States
- Volunteers
- 8 people
- Sponsor
- Panagiotis Konstantinopoulos, MD, PhD
Breast Cancer, Endometrial Cancer
Metformin and Temsirolimus in Treating Patients With Metastatic or Unresectable Solid Tumor or Lymphoma
RATIONALE: Metformin and temsirolimus may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
- Conditions
- Breast Cancer, Endometrial Cancer, Kidney Cancer, Lung Cancer
- Trial name
- NCT00659568
- Testing
- metformin hydrochloride, temsirolimus
- Where
- Canada
- Volunteers
- 28 people
- Sponsor
- London Health Sciences Centre
Endometrial High Grade Endometrioid Adenocarcinoma, Fallopian Tube Clear Cell Adenocarcinoma
A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer
This phase I trial studies the side effects and best dose of peposertib when given together with pegylated liposomal doxorubicin hydrochloride in treating patients with high or low grade ovarian cancer that has come back after a…
- Conditions
- Endometrial High Grade Endometrioid Adenocarcinoma, Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube High Grade Serous Adenocarcinoma
- Trial name
- NCT04092270
- Testing
- Biospecimen Collection, Computed Tomography, Echocardiography Test
- Where
- 11 sites in United States
- Volunteers
- 55 people
- Sponsor
- National Cancer Institute (NCI)
Estrogen Receptor Positive, Postmenopausal
Ribociclib and Letrozole in Treating Patients With Relapsed ER Positive Ovarian, Fallopian Tube, Primary Peritoneal, or Endometrial Cancer
This phase II trial studies how well ribociclib and letrozole work in treating patients with estrogen receptor (ER) positive ovarian, fallopian tube, primary peritoneal, or endometrial cancer that has returned (come back) after a…
- Conditions
- Estrogen Receptor Positive, Postmenopausal, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma
- Trial name
- NCT02657928
- Testing
- Laboratory Biomarker Analysis, Letrozole, Ribociclib
- Where
- 3 sites in United States
- Volunteers
- 40 people
- Sponsor
- Mayo Clinic
Non-Small Cell Lung Cancer, Breast Cancer
Myeloprotection With Trilaciclib in Pan-cancer Population
The goal of this open-label randomized controlled study is to assess the myeloprotective effect of trilaciclib in pan-cancer population.
- Conditions
- Non-Small Cell Lung Cancer, Breast Cancer, Endometrial Cancer, Cervical Cancer
- Trial name
- NCT06297811
- Testing
- Trilaciclib Injection, Paclitaxel, Carboplatin
- Where
- China
- Volunteers
- 132 people
- Sponsor
- Sun Yat-sen University
Carcinoma
A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Japanese Participants With Primary Advanced or Recurrent Endometrial Cancer
The goal of this clinical trial is to understand the effectiveness of dostarlimab and carboplatin-paclitaxel followed by dostarlimab monotherapy in participants with endometrial cancer
- Trial name
- RUBY-J (NCT06317311)
- Testing
- Dostarlimab, Carboplatin, Paclitaxel
- Where
- 15 sites in Japan
- Volunteers
- 41 people
- Sponsor
- GlaxoSmithKline
Endometrial Cancer
Phase 2 Study Evaluating the Efficacy of the Combination of DKN-01 (DKK1 Inhibitor, Leap Therapeutics) and Pembrolizumab in the Treatment of Advanced or Recurrent Endometrial Cancer
To learn if the combination of DKN-01 and pembrolizumab can help to control advanced or recurrent endometrial cancer.
- Trial name
- NCT05761951
- Testing
- DKN-01, Pembrolizumab
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- M.D. Anderson Cancer Center
Endometrial Cancer
Doxorubicin, Paclitaxel, and Carboplatin in Treating Patients With Primary Stage III, Stage IV, or Recurrent Endometrial Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00006377
- Testing
- carboplatin, doxorubicin hydrochloride, paclitaxel
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center